Intrathecal Enzyme Delivery via CSF Diffusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies struggle to effectively deliver therapeutic agents across the blood-brain barrier, limiting the treatment of central nervous system (CNS) diseases, particularly lysosomal storage disorders, due to the barrier's restrictive nature and lack of effective delivery methods.
Innovation Solution
Intrathecal administration of a replacement enzyme at high concentrations (e.g., greater than 5 mg/ml) into the cerebrospinal fluid, using simple saline or buffer-based formulations, allows for extensive diffusion across brain regions without inducing severe immune responses, enabling efficient CNS delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intravenous enzyme replacement therapy is administered, then systemic distribution is achieved, but the blood-brain barrier prevents adequate delivery to CNS tissues
Solution Approach 1:
The patent uses the cerebrospinal fluid (CSF) as an intermediary medium to deliver the enzyme replacement therapy to the CNS. By injecting the enzyme into the CSF space via lumbar puncture, the therapy bypasses the blood-brain barrier entirely and allows the enzyme to diffuse through the CSF to reach affected brain and spinal cord tissues.
Solution Approach 2:
The patent segments the delivery system by separating the administration route from the systemic circulation. Instead of relying on intravenous delivery through the bloodstream, the enzyme is delivered directly into the CSF space, creating a separate delivery pathway that avoids the blood-brain barrier restriction.
2Quantity of substance
If direct intra-cranial injection is used to bypass the blood-brain barrier, then brain delivery is achieved, but the risk of complications increases
Solution Approach 1:
Instead of injecting directly into the brain parenchyma (intra-cranial), the patent inverts the approach by injecting into the sub-arachnoid space (lumbar region) and allowing the enzyme to diffuse through the CSF to reach the brain. This reverses the traditional direct injection approach and eliminates the associated risks.
Solution Approach 2:
The CSF acts as an intermediary that carries the enzyme from the lumbar injection site to the brain and spinal cord tissues, eliminating the need for direct intra-cranial injection and its associated complications.
3Quantity of substance
If intrathecal injection is used to deliver enzyme to CSF, then CNS delivery is improved, but the enzyme binds tightly to ependymal lining preventing diffusion
Solution Approach 1:
The patent modifies the enzyme formulation by conjugating the enzyme with mannose-6-phosphate (M6P) or other targeting moieties that change its binding characteristics. This parameter change prevents tight binding to the ependymal lining while maintaining the ability to cross the ependymal barrier and reach CNS tissues through the CSF.
4Quantity of substance
If high concentration enzyme is administered intrathecally, then therapeutic effect is improved, but immune response may increase
Solution Approach 1:
The patent changes the physical and chemical parameters of the enzyme formulation, including concentration, pH, and formulation excipients, to optimize delivery while minimizing immune response. The high concentration is achieved through careful formulation that maintains enzyme stability and reduces immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a clinically desirable and patient-friendly method for treating CNS diseases by achieving therapeutic enzyme levels in various brain tissues and peripheral organs, effectively addressing the challenges of traditional delivery methods.
Implementation Method 1
the enzyme effectively and extensively diffuses across various surfaces and penetrates various regions across the brain, including deep brain regions
Data Source
Figure 1
Figure 2A~2B
Figure 2C
AI summary
The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.